| Test |
Test Description To Print |
Test Code |
Unit |
QC Cost |
Result Type |
Round off |
Numeric Result Type |
Assay Content |
Microbial |
Retest |
Test for Water/LOD |
| # 100 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| # 20 mesh |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| #200 mesh |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| #60 mesh |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| % Single Maximum unknown impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| % Total unknown impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| (a) By Light Obscuration Particle Count Test ≥ 10µm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| (a) Sulbactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| (b) By Light Obscuration Particle Count Test ≥ 25µm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| (b) Cefoperazone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| (on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| (on as is basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| *Ink lifting test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| -RRT 0.86 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| -RRT 1.27 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| -RRT 1.39 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| -RRT > 2.0 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| . p- toluene sulphonamide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 1) Lidocaine Hydrochloride BP: 10.0 mg/mL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 1)Diethylene glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 1,4 Dioxane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| 1-vinylpyrrolidin-2-one |
|
|
|
0 |
Character |
|
|
N |
N |
Y |
|
| 12- hydroxyl stearic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 12-oxosteric acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2) Ethylene glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2) Sodium Chloride BP: 7.0 mg/mL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2,6 Dimethylaniline |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2- Ethylhexanoic acid by GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2-Hydroxy-2-methyl-proplophenone (2-HMP) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| 2-methylbut -2-ene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2-Propanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2-Pyrrolidone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 28.5 ml to 31.5 ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 2D Code |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 3) Methyl Paraben BP: 1.0 mg/mL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 45MIC x 300MM LDPE SHRINK FILM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 5 Ply C/Box 410X280X215 Oflox -D |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 5-Benzyl-3,6-dioxo-2-piperazineacetic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 6- Bromopenicillanic Acid Sulphone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| 7-Aminocephalosporanic acid (if present) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A Assay (Initial): by HPLC Each 5 ml reconstituted suspension contains:Cefixime IP (as Trihydrate) equivalent to Anhydrous Cefixime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A NLT 75% (D) i.e 80 % of the stated amount of Cefixime released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A ) Assay (in %) (Each vial contains: Ceftriaxone Sodium Eq. to Ceftriaxone |
|
|
|
0 |
Numeric |
|
Range |
N |
N |
N |
|
| A ) By chemically |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) A)When sample is strongly heated becomes pale yellow, the colour discharge on cooling. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Assay (Initial): by HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Assay (Initial): by HPLC Each 5 ml reconstituted suspension contains:Cefixime IP (as Trihydrate) equivalent to Anhydrous Cefixime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By IR |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Cefixime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Cefixime released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| a) 2.5 ml marking |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Assay (Initial): Each 5 ml reconstituted suspension contains: Cefixime Trihydrate IP equivalent to Cefixime anhydrous 50 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Assay (Initial): Cephalexin IP equivalent to anhydrous Cephalexin 125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Assay (Initial):Each 5 ml of the reconstituted suspension contains:Cefixime IP as Trihydrate equivalent to anhydrous Cefixime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Average net volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By Banzoates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By Colour test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By Freezing point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By IR |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By IR (method I) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By Magnesium test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By microscopy |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By Relative density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By Specific rotation |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By TLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By UV |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By visual inspection |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) By visual test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Chloride Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Clarity with water |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Escherichia coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Freezing point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) I- Indication for a polymeric compound |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| a) Less than 0.5 % Particles should retain on #60 mesh ASTM (250µm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Melting point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) NLT 50 % (Q) i.e 55 % of the labeled amount of cefuroxime released in 15 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A) Sulbactam (activity) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| A) Total aerobic microbial count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)1 For Cefixime % Single Maximum Impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)2 For Cefixime % Total Impurities: |
|
|
25 |
250 |
Character |
|
|
Y |
Y |
Y |
|
| A)Assay (Initial): by HPLC Cefixime USP (as Trihydrate) equivalent to Anhydrous Cefixime 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)Assay (Initial): by HPLC Each 5 ml reconstituted suspension contains: Cefixime Trihydrate IP equivalent to Cefixime anhydrous 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)Assay (Initial): by HPLCEach 5 ml reconstituted suspension contains: Ofloxacin IP 50 mg: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)Assay (Initial): Cefpodoxime Proxetil IP equivalent to Cefpodoxime 50 mg.. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)Assay by HPLCEach 5 ml of the reconstituted suspension contains:Cefpodoxime Proxetil IP equivalent to Cefpodoxime 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)Assay by weight: Ceftriaxone USP on Anhydrous Basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)Average net volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)By Chemical |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| a)NLT 60 % (Q) i.e 65 % of the labeled amount of cefuroxime released in 15 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A)NLT 90% of L.C the stated amount of Cefixime released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A-. Stearic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A. Benzene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A. II –Distinction from locust Bean Gum |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A. Thiazolylacetyl glycine oxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A.) Glass Grain Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A1) For Tazobactam % Single Maximum unknown impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| A2) For Tazobactam % Total unknown impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Absorbance |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acetic Acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acetone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acetone(%w/w) By GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acetonitrile |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acetyl value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acid value of the fatty acids |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acid insoluble substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acid soluble Substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acid Value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| acid1 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acidity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acidity or Alkalinity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acidity or Alkalinity (pH ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acidity or alkalinity (B.)Methyl orange indicator |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Acidity or alkalinity( A.)BPR indicator |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Adhesive |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Adhesive Coating |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Adhesive Gsm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Adhesive layer GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Adhesive Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Adsorption Capacity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aldehydes |
|
|
|
0 |
Character |
|
|
N |
N |
Y |
|
| Aldehydes and Ketones |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Alignment |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Alkaline impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Alkalinity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| All other Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Alu foil gsm* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Alu foil Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aluminium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aluminium (Chemical Method) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aluminium GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aluminium Thickness(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aluminum (as AL) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Aluminum, calcium & related elements |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ammonia Compounds |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ammonium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Amoxicillin Related Compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Anhydrous Di-sodium hydrogen |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Antimony |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any Individual Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any Individual unspecified impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any maximum impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any other highest unknown impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any other Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any Other Individual Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| any other of fatty acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any other secondary impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Any Unspecified degradation product |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance After Constitution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance of Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance of solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance of solution (A.)Clarity of solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance of solution (B.)Colour of solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance of solution (Clarity and colour of solution) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Appearance of solution of the fatty acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Apperance of solution (1.2 % w/v solution in water) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| AQL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Arachidic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Arsenic |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Arsenic (as AS ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Arsenic (as As) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Arsenic Test(µg) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Artwork code |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ash |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay
Potency (HPLC) withdrawable basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay ( In House ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay ( on ignite basis ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By Potentiometry) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (mg per vial) Each vial contains:Cefoperazone Sodium IPEq. to Cefoperazone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay ( Bacterial count ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay ( By GC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay ( on anhydrous basis ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (% Lable claim) Each vial containes: Ceftriaxone Sodium IP eq. to Ceftriaxone |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Assay (% w/w) by HPLC (as Tazobactam on anhydrous basis) |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Assay (% w/w) by HPLC (on anhydrous basis and acetone free basis) |
|
|
% |
0 |
Character |
|
|
N |
N |
N |
|
| Assay (% w/w) by HPLC (on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (% w/w) by HPLC (on as is basis) |
|
|
|
0 |
Character |
|
|
Y |
N |
N |
|
| Assay (% w/w) by HPLC* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (%w/w, on anhydrous basis, as Enmetazobactam ( By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (After 7th day) by HPLC Each 5 ml of the reconstituted suspension contains:Cefpodoxime Proxetil IP equivalent toCefpodoxime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By HPLC %(on dried and sodium carbonate-free basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay (by HPLC µg/mg of Cefpodoxime on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By HPLC) (Cefixime on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By HPLC) (on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By HPLC) Content of Ceftazidime on as is basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay (By HPLC) On as is basis
Avibactam content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay (By Ion chromatography)
Content of Sodium chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay (By titration) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By Titrimetry) On dried basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (By Titrimetry)Magnesium(on dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (g/vial)Each vial contains:Ceftriaxone Sodium USP eq. to Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (mg per vial ) Chaque flacon contient:Ceftriaxone Sodium BP Eq. to Ceftriaxone . |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (mg per vial) Each vial contains: Cefuroxime Sodium IP eq. to Cefuroxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (mg per vial)Each vial contains:Ceftriaxone Sodium BP Equivalent to Ceftriaxone 1 g |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (mg per vial)Each vial contains:Ceftriaxone Sodium BP Equivalent to Ceftriaxone 500 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (mg/vial)Each vial contains:Ceftriaxone Sodium IP (Sterile)eq. to Ceftriaxone 250 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (On Anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay (on anhydrous basis): By potentiometry. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (on ignite basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (on the anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay (on the dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay : by HPLC Each film coated tablet contains: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ASSAY : By Titrimetry |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay By AAS (%w/w) (Content of Galactomannans) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay By GC |
|
|
|
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Assay by HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Assay By HPLC (in µg/mg, on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay by HPLC (on dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay by tirimetry |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay by Titration ( on dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay of Ceftazidime ( By HPLC , on as is basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay of Ciprofloxacin |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay of Dexamethasone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ASSAY OF Si02 (%) Calculated on the ignite basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay on 14th day of reconstitution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay on dried basis % w/w |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay pyruvoyl groups ( on dried basis ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay(w/w) by HPLC (ceftriaxone on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: by HPLC Each 5 ml of the reconstituted suspension contains: Cefadroxil IP Equivalent to anhydrous Cefadroxil 125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: by HPLC, Each 5 ml of the reconstituted suspension contains: Cefuroxime Axetil USP equivalent to Cefuroxime 125 mg: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: By Titrimetry: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: By titrimetry: calculated on the dried basis. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: By Ultraviolet and visible absorption spectrophotometry: calculated with reference to the dried substance. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Each vial contains Cefotaxime sodium (sterile) USP eq. to Cefotaxime 1g |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Each vial contains Cefotaxime sodium (sterile) USP eq. to Cefotaxime 500 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Ratio of Alkyl components. (By: HPLC.) n-C12H25 homolog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Ratio of Alkyl components. Total amounts of the n-C12H25 & n-C14H29 homolog. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Ratio of Alkyl components.n-C12H25 homolog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Ratio of Alkyl components.n-C14H29 homolog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay: Total alkyl benzyldimethylammonium chlorides. (By: Titrimetry) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay:(A mixture of Epimers A and B C25H34O6, On dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Assay:. by HPLC Each 5 ml of the reconstituted suspension Cefadroxil IP Equivalent to anhydrous Cefadroxil 250 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Average Fill Weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Average filled Volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Average weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Average weight (Only cap) (g) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Avg.weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Avibactam content ( By HPLC on as is basis ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Avibactam Sodium Content (By HPLC on as is basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Azithromycin Impurity (B) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Azithromycin IP 250 mg: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Sodium Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Assay (After 7th day)by HPLC Each 5 ml reconstituted suspension contains:Cefixime IP (as Trihydrate) equivalent to Anhydrous Cefixime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| b) 5 ml marking |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Acid value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Assay (After 7th day) by HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Assay (After 7th day) Cephalexin IP equivalent to anhydrous Cephalexin 125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Assay (After 7th day) Each 5 ml of the reconstituted suspension contains:Cefixime IP as Trihydrate equivalent to anhydrous Cefixime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Assay (After 7th day): Each 5 ml reconstituted suspension contains: Cefixime Trihydrate IP equivalent to Cefixime anhydrous 40 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Assay (in %) (Each vial contains: Sulbactam Sodium USP eq. to Anhydrous Sulbactam) |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| B) Assay (in %) Sulbactam Sodium USP Eq.to Sulbactam |
|
|
(%w/w) |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| B) Azithromycin |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Azithromycin by HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Sodium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Acid Value of Fatty Acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Assay Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Chemical |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Chemical test 1 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Colour test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By IR |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Light obscuration particle count test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Light obscuration particle count test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Melting point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Refractive index |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By TLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By UV |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) By Viscosity: Degree of polymerization |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Cefoperazone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| B) Cefoperazone (activity) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| B) Clarity with acetic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Hydroxyl value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Individual net volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Limit of Diethylene glycol and ethylene glycol: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) NLT 70 % (Q) i.e 75 % of the labeled amount of cefuroxime released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) NLT 75% (D) i.e 80 % of the stated amount of Ofloxacin released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| b) NMT 20.0% particles should retain on #200 mesh ASTM (75µm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Ofloxacin released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Salmonella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Salmonellae and Shigella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Sodium salt Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Test of sodium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Total fungal count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B) Total molds and yeasts count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)1 For Ofloxacin % Single Maximum Impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)2 For Ofloxacin % Total Impurities: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Assay (After 7th day of reconstitution) by HPLC Cefixime USP (as Trihydrate) equivalent to Anhydrous Cefixime 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Assay (After 7th day) by HPLC Cefpodoxime Proxetil IP equivalent to Cefpodoxime 50 mg.. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Assay (After 7th day) by HPLC Each 5 ml reconstituted suspension contains:Cefixime Trihydrate IP equivalent to Cefixime anhydrous 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Assay (After 7th day) by HPLCEach 5 ml reconstituted suspension contains: Cefixime Trihydrate IP equivalent to Cefixime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Assay (After 7th day) by HPLCEach 5 ml reconstituted suspension contains: Cefixime Trihydrate IP equivalent to Cefixime anhydrous 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Assay (After 7th day) by HPLCEach 5 ml reconstituted suspension contains: Ofloxacin IP 50 mg:. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)By HPLCEach 5 ml of the reconstituted suspension Assay (After 7th day) contains:Cefpodoxime Proxetil IP equivalent to Cefpodoxime 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| b)NLT 75 % (Q) i.e 80 % of the labeled amount of cefuroxime released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)NLT 90% of L.C the stated amount of Ofloxacin released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Solution A with strong hydrogen peroxide solution produces orange- red colour . |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Specific Microbial Limit (Pathogens) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B)Total fungal count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B- The sum of stearic acid and palmitic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B. Total unknown impurities apart from 2-butanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B.Degree of Polymerization |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B.Thiazolylacetyl glycine oxime acetal |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B.Total Impurities other than 2-Butanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B1) For Ceftriaxone % Single Maximum unknown impurity: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B1) for ≥ 10µ |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B2) For Ceftriaxone % Total unknown impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| B2) for ≥ 25µ |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bacterial Endotoxin |
|
|
|
0 |
Character |
|
|
N |
Y |
N |
|
| Bacterial Endotoxin (Endotoxin Unit per mg for both ) |
|
|
|
0 |
Character |
|
|
N |
Y |
N |
|
| Bacterial Endotoxin Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bacterial Endotoxin test: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Barcode |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Barium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Base colour |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Base Outer Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Benzene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Benzene and related substances by GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Benzoate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Benzoic Acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bile tolerant gram-negative Bacteria |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bled Uniformity. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Bleeding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Board Grammage |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Board quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Body Outer Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Boiling Range |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bottom Layer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bottom Outer Dia (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Braille Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bromide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bromide and Iodide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bromide: By Visible absorption spectroscopy |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bromoacetyl analog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE BACK LABEL TRANSPULE |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE BACK LABLE TRANSPULE |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE BACK LABLE TRANSPULE 271771 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Budate Carrugated Box 525x340x305 mm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE CARTON |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE FRONT LABEL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE POUCH LABEL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDATE TRANSPULE PRINTED INSERT |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| BUDECORT RESPULES 0.5 MG POUCH LABEL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Buffering Capacity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Buffering capacity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bulk Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bulk Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Burst factor |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Burst strength |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Bursting Strength (kg/cm2) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| By IR |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| c) 10 ml marking |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) Absorbance at 430nm (10 % w/v solution in water) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By Chemical |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By Chemical test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By chemical test 2 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By IR# |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By Sodium test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By TLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) By UV |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) Escherichia coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) Pathogen count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) Pseudomonas aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C) Test of sodium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C)Escherichia coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C)Solution A with zinc granules produces a violet blue colour. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| C. Cefdinir Sulfoxide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cadmium ( as Cd ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cadmium (as Cd) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| calcium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Calcium and Magnesium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Calcium and magnesium ( Calculated as Ca) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Calcium and magnesium: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Caliper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Caliper(thickness) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cap Fitment & Sealing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cap Height |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cap ID |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cap OD |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cap weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Caproic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Caprric acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Caprylic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Carbonates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefadroxil Impurity-A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefadroxil Impurity-B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefadroxil IP Equivalent to anhydrous Cefadroxil 250 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefadroxil IP equivalent to Anhydrous Cefadroxil 500 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefadroxil IP equivalent to Anhydrous Cefadroxil125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefdinir USP equivalent to anhydrous Cefdinir 300 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| cefepime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefepime Hydrochloride IP eq. to Cefepime |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Cefepime Impurity (A) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefepime Impurity (B) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefepime Related Compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefepime Related Compound C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefetamet |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime 200 mg:Ofloxacin IP 200 mg: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate IP equivalent to anhydrous |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate IP equivalent to anhydrous Cefixime 100 mg.. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate IP equivalent to anhydrous Cefixime 200 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate IP equivalent to Cefixime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate IP equivalent to Cefixime (Anhydrous) 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate IP equivalent to Cefixime anhydrous 50 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate USP equivalent to anhydrous Cefixime 200 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime Trihydrate USP equivalent to Cefixime (Anhydrous) 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime USP (as Trihydrate) equivalent to Anhydrous Cefixime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefixime USP (as Trihydrate) equivalent to Anhydrous Cefixime 50 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefoperazone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Cefoperazone Sodium IP Eq. to Cefoperazone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefoperazone Sodium USP Eq. to Cefoperazone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefotaxime dimer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefotaxime open ring lactone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefotaxime related compound E |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefotaxime sodium (sterile) USPeq. to Cefotaxime 500 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefotaxime Sodium equivalent to Cefotaxime in (%) Labeled Amount |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefpodoxime Proxetil IP equivalent to Cefpodoxime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefpodoxime Proxetil IP equivalent to Cefpodoxime 100 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefpodoxime Proxetil IP equivalent to Cefpodoxime 200 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefpodoxime Proxetil IP equivalent to Cefpodoxime 50 mg.. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftazidime pentahydrate equivalent to Ceftazidime (C22H22N6O7S2) In (%) Labeled Amount |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone -3-ene isomer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone benzothiazolyoxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone E-Isomer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone Sodique BP (Sterile) Equivalent to Ceftriaxone 1000 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone Sodium IP (Sterile) eq. to Anhydrous Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone Sodium IP eq. to anhydrous Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone Sodium IP Eq. to Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone Sodium USP eq. to Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone triazine analog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ceftriaxone USP On Anhydrous Basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime axetil dimer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil D³-isomers |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil E-isomers |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil equivalent to Cefuroxime (C16H16N4O8S), in mg (%) Labeled amount |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil IP equivalent to |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil IP equivalent to Cefuroxime 250 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil IP equivalent to Cefuroxime 500 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil USP equivalent to |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil USP equivalent to Cefuroxime 125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime Axetil USP equivalent to Cefuroxime 500 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cefuroxime lactone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Chlorides |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Chlorinated Compounds |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Chromatographic Purity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Chromatographic Purity (%) (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Chromatographic purity* (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cinnamic Acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| CIPLOX-D EYE/EAR DROP CARTON 10 ML |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| CIPLOX-D EYE/EAR DROPS 10 ML LABELS |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Claim |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Clarity of Solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cleanliness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Code no is missing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Code No. is missing or is not in accordance with the standard |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Color (425nm,cmcell) 6.2ml WFI/vial |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Color index
(10% solution w/v ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Color of Reconstituted Solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| color of solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| colorant |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Absorbance |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Index |
Absorbance of a 5% w/v solution of sample at 240nm is not more than 0.060. |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Index (5g in 50 ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Lake Sun Yellow |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour lifting |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Of Flip Off Disc |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour of solution (By UV) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour scheme |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Shade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| colour shade of kraft paper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colour Value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Colouring matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Combined Ether Extracts |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Compound A (Aminosulfinic acid) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Compound A (Aminosulfinic acid)Individual Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Compressibility index |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Compression strength |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Condition of Core |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Condition of Roll |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Conductivity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Congealing Temperature |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Constituted solution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Constituted solution (Clarity of solution ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Constituted solution (Completeness & Clarity of Solution ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Constituted Solution, Completeness and clarity of solution (1g in 10 ml ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of 2,3, cyclopentane 5 pyridine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of Water soluble material |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of Arginine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of Avibactam sodium equivalent to Avibactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of Cefepime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of Ceftazidime on as is basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of ceftazidime pentahydrate equivalent to ceftazidime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Content of Glycopyrrolate equivalent to Glycopyrronium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Core Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Core used |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Creasing Quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Crystallinity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cutting and Creasing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Cyclohexane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D) By Chemical |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D) Chemical test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D) Salmonella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D) Staphylococcus aureus |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D) TLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D)By Melting point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D)Salmonella spp. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D-Phenylglycine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D. Cefdinir thiazine analog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D10 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| D3- isomers |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| d50 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| d90 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| d97 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Deacetylcefotaxime lactone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Deacyl Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Degree of Polymerization |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Degree of substitution (on dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Deliverable volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Descarbamoyl – cefuroxime Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Descorbomoyl Cefuroxime Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Description |
A clear or almost clear, Oily, yellowish or brownish yellow liquid, Odour faint and Charateristic. |
|
|
0 |
Character |
|
|
N |
N |
Y |
|
| Design |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dexamethasone content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dextrins |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Diameter (in mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Diameter Of Flip- Off Disc |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Diameter Of Wad(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Diastereoisomer ratio |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dichloromethane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Didehydroglycopyrrolate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Differential scanning calorimetry |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Diglyme ether |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Dimethyl Formamide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Disintegration Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dispersion Time |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dissolution (% Drug Release) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dissolution By UV |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Distillation Range |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Dodecane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Dye Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E) By chemical |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E) Pseudomonas Aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E)Pseudomonas Aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E- isomers |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E-Cefotaxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E. Cefdinir impurity 1 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| E. coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each 5 ml of the reconstituted suspension contains:Cephalexin IP equivalent toanhydrous Cephalexin 125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each film coated tablet contains: Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each film coated tablet contains:Cefpodoxime Proxetil IP equivalent to Cefpodoxime200 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each Hard gelatin capsule contains:
Amoxycillin Trihydrate IP eq. to amoxycillin |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Each tablet contains: Cephalexin equivalent to Anhydrous Cephalexin 250 mg. |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
N |
| Each tablet contains:Cephalexin equivalent to Anhydrous Cephalexin 125 mg. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each vial contains Cefazolin sodium equivalent to Cefazolin in mg In (%) Labeled Amount |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each vial contains Cefuroxime Sodium equivalent to Cefuroxime (C16H16N4O8S), in mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each vial contains: Ceftriaxone Sodium IP Eq. to Ceftriaxone |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Each vial contains: Ceftriaxone Sodium USP eq. to Ceftriaxone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each vial contains:Cefotaxime Sodium IP eq. to Cefotaxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each vial contains:Cefotaxime sodium USP eq. to cefotaxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Each vial contains:Cefuroxime Sodium IP eq. to Cefuroxime |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Elasticity |
Identification |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Enantiomeric Purity:
By HPLC
(S)- Salbutamol Sulphate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Enmetazobactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Enterobacteriaceae |
Should be absent |
|
|
0 |
Character |
|
|
N |
Y |
N |
|
| Epimer A: By HPLC |
Not Less Than 40.0 and Not More Than51.0 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Escherichia coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ethanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ethanol by GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ether -Soluble Substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ether Extractable matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ethyl Acetate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ethylene dichloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Ethylene glycol & diethylene glycols( by GC ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Extractable Heavy metals |
Extractable Heavy metals |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Extractable Volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Extractable ZINC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| F) Staphylococcus |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| F)Staphylococcus aureus |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| F. 3-Methyl Cefdinir |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Face Paper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Face stock |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Fatty acid composition ( by GC ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ferrocyanide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fill weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Fill weight (Average) (20 vials) (Individual) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Fill weight (Average) (20 vial) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Fill weight (Average) (20 vials) (Individual) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| First substrate (PET) GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fitting |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fitting of screw cap with bottle |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flange Thickness (Collar) |
Flange Thickness (Collar) |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flavour / odor |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flavour Strength |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flavour/Odor |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fluorences |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fluorescent Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fluoroquinolonic acid: (By TLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flute |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flute 1 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Flute 3 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| flute2 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fluticasone acetate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Fluticasone acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Fluticasone acid Propionate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Foil thickness (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Folding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Folding Quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Folding Size (Width mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Folding Size (Length mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| for ≥ 10µ |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| for ≥ 25µ |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For , nominal volume of more than 5 ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| for > 10 ml volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For Arginine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For Avibactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For Cefepime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For CEFIXIME |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For Ceftazidime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For Glycopyrronium < By HPLC> |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| For Ofloxacin |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| for ¡Ü 10 ml volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| For, nominal volume of 5 ml or less than 5 ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Foreign Amines |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Foreign matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Foreign matter(6.2 ml of WFI/vial) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Formic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fourth substrate (Poly) GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fragmentation Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Free Chlorine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Free Dye Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Free fatty acids |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Free stearic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Freezing point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Friability |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Fumaric Acid Content: (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| fungus(cfu/g) |
Not more than 100 |
|
|
0 |
Character |
|
|
N |
Y |
N |
|
| G. Cefdinir Related compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Gap between labels |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Glass Grains Test(ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Glucose and invert sugar |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Glycopyrrolate Related Compound B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Glycopyrrolate Related Compound C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Glycopyrrolate Related compound I |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Glycopyrrolate Related Compound L |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Grain Direction |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Gramage Of Aluminium Foil Without VMCH/HSL/Universal HSL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GramageOf VMCH/HSL/Universal HSL Coating |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage (gsm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage Of Polythene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage Of Aluminium Foil Without Polythene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Bottom Layer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of each ply |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of each ply Layer-2:- NLT 126 GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of each ply Layer-3:- NLT 126 GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of each ply Layer-4:- NLT 126 GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of each ply Layer-5:- NLT 126 GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Layer-2 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Layer-3 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Layer-4 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Layer-5 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Middle Layer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Top Layer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Grammage of Top Ply |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM Adhesive |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM Adhesive Paper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM Face Paper : |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM Release Paper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM (gm/sq. meter) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM of face stock |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GSM Of Paper (G/m2) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| GSM of PVDC Coating |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Guage of aluminium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| GUM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| H.Cefdinir Related compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Halogenated compounds |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hardness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hausner ratio |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Heat seal lacquer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Heat seal lacquer coating part |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Heavy metals |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Height |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Height (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Height of Partition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Height of plastic Disc (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Height of Seal Aluminium portion (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hexane (ppm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Highest Individual Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| HSL coating grammage |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| HSL GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| HYDRAZINE |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hydrolytic Resistance (ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hydroxyl value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hydroxypropoxy |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Hydroxypropyl Group |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| i) Ethylene Glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| i) Escherichia coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| i) Ethylene Glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| i)Methonol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| i)Total aerobic microbial count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| I. Cefdinir Related compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ID of Mouth |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification |
A blue colour is produce on treatment of the sample with chloroform, Potassium thiocyanate and Cobal |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification B : By Thin layer chromatography |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification C |
The sample solution decolourises bromine water. |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification C : By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification (By : IR ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification (By Ferric Oxide Test) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification (By TLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| IDENTIFICATION A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification A For Sodium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Identification B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification B (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification B For Chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Identification B: (By TLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification By GC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification By uv |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification D |
The Infrared absorption spectrum of sample is concordant with the infrared absorption spectrum of Po |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification for aluminium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification of Nitrocellulose Coating |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification of PE ( sealant layer ) by IR |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Identification: (By UV) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ii) Diethylene Glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| ii) Diethylene Glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ii) P.aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ii)Ethanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ii)Total molds and yeasts count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| iii) Triethyene Glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| iii) S.aureus |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| iii) Triethylene Glycol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| iii)Acetone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| IMPURITY -A By -HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity A (BY TLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Impurity B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity D |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity E |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity F |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Impurity G |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Impurity H |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Impurity I |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Inadequate space for batch details |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Individual (GSM) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Individual (GSM)* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Individual Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Induction Wad Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Initia pH: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ink Details |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ink Grade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ink lifting test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ink Shade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inner flap Height(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inner core diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inner diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inner Diameter of Aluminium Seal (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inner Height of Aluminium seal |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inorganic Phosphate : By ultraviolet and visible absorption spectrophotometry Calculated as Po4 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Inside Height (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Insoluble in HCl |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Insoluble substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Internal Dia (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Internal Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Internal Mouth Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Internal Mouth Diameter(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Iodide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Iodides |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Iodine value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Iron |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Iron Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Iso-propanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Isomer Ratio (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Isopropyl Alcohol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| iv) Salmonella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| iv)Isopropyl Alcohol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| J. Cefdinir Related compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| K-value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| K. 7-s Cefdinir |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| L. Cefdinir Lactone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Label grade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Label manufacturer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| LABEL TAMPER EVIDENT FOR MID-MIDAS |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Labels with missing print |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lactic Acid Bacillus 60 million Spores |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lactic acid producing capacity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Laminated ALU Foil |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lauric acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| LDPE film Grammage |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lead |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lead (as Pb ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lead (as Pb) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lead and Heavy Metals |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Leak Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Length |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Length (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Length After Folding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Length of Partition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Less than 10 ml volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Levosalbutamol Assay Duolin |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Light Absorption |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Light absorption (Solution A) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Light Absorption (by UV) at 440 nm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Light absorption : by ultraviolet and visible absorption spectrophotometry |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit (In % w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of , Benzaldehyde |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Aluminum %w/w |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of amines and amine salts (By: potentiometry) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Benzyl Alcohol (By: HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of bromides |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Limit of Cadmium (ppm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Calcium %w/w |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Chloromethyl benzene : |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Erythro Isomer; (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Hydrogen chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Iron %w/w * |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Lead ppm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Methacrylic Acid and Ethyl Acrylate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of N – Methyl pyrrolidine (%w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of Nickel (ppm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of nitrilotriacetic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Limit of Nonvolatile Residue |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Limit of oxalic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Limit of phosphates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Limit of Pyridine % (w/w) * |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Liner |
|
|
GSM |
0 |
Character |
|
|
N |
N |
N |
|
| Liner GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Linoleic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Linoleic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Linolenic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Lip Thickness (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Lock Property |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Locking |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Locking Quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| LOD ( for 1 hr at 105 ° C ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| LOD(%w/w) |
|
|
%w/w |
0 |
Character |
|
|
N |
N |
N |
|
| Loss on Attrition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Loss on drying at 110ºC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Loss on Drying (% w/w) (Use 1.0 g sample dry at 105ºC for 3 hours.) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Loss on Drying (% w/w) (Use 1g sample dry at 100¢ªC to 105¨¬C for 3 hours.). |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Loss on Drying (% w/w)(Use 1g sample dry at 100¢ªC to 105¨¬C for 3 hours.). |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Loss on Drying (%w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Loss On Ignition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| M. Cefdinir Related compound B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Magnesium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Magnesium and alkaline-earth
metals |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Manufacturing Joints |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Marking of 2.5ml,5ml&10ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Material |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Material Of Flip off Disc |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| MBT Content ( By HPLC, ppm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| medium |
|
|
micro |
0 |
Character |
|
|
N |
N |
N |
|
| Melt flow index |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Melting Point |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Melting range |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mercury |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mercury ( as Hg ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mercury (as Hg) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Method-IITriethylamine Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methoxy |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methoxyiminofuranyl acetic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methyl Bromide Content: (By GC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methyl Isobutyl Ketone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methylene Chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Methylene Dichloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Micro Text embossing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial Contamination |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial Enumeration test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial Enumeration test (bioburden) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial enumeration tests |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test A)Total viable count ( 1) Total Aerobic Microbial count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test A)Total viable count ( 2)Total Combined Yeast and Mould count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test B) Test for specified microorganism(2) E.coli |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test B)Test for specified microorganism (1) Bile tolerant gram- negative bacteria |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test B)Test for specified microorganism (3) Salmonella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test B)Test for specified microorganism(4)Pseudomonas aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test B)Test for specified microorganism(5)Staphylococcus aureus |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial test B)Test for specified microorganism(6)Candida albicans |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbial Tests |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbiological examination of non-sterile products: Aerobic Microbial count: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbiological examination of non-sterile products: Combined Yeasts and Molds count: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbiological examination of non-sterile products: Total aerobic microbial count. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Microbiological examination of non-sterile products: Total combined Yeast and Molds count. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Middle Layer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Middle Layer-1 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Middle Layer-2 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Middle Layer-3 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Middle layer-4 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Middle Layer-5 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mineral acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mix up of other product |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mix up of other product Cartons |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mix up of other product Labels |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Moisture % |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Molar Substitution |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Monocalcium & Tricalcium Phosphates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Monosodium phosphate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Morphline Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mouth Inner Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Mouth Outer Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Myristic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| N,N-Dimethylacetanide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| N,N-Dimethylaniline (ppm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| n-Butyl acetate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| n-Decane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| N-Hexane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| N.Cefdinir isoxazole analog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Name of board |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Neck Diameter over collar(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neck Diameter over thread(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neck Height (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neck Inner Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neck Outer Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neck Ring OD |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neck thread OD |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Neotame Impurity A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Net Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Nickel |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Nitrate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Nitrites |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Nitrogen (Method C) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Nitrogen (Method II ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Nitrogen (on anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| NLT 75% (D) i.e 80 % of the stated amount of Azithromycin released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| NLT 90% of the stated amount of Cefixime released in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No of colour |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No of contener |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of Net |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of corrugated plates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of cut lock |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of Piles |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of ply (No’s) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of Slots |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| No. of Track |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Non volatile Matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Non volatile residue |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Non-esterified alcohols |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Not less than 50% (Q) of label claim shall dissolve in 15 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Not less than 60% (Q) of label claim shall dissolve in 15 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Not less than 70% (Q) of label claim shall dissolve in 45 min. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Not less than 70% (Q) of label claim shall dissolve in 45 min.. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Number Of Bridges |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Number of joints in a roll |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Number of Joints per Roll |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| o-toluene sulphonamide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| O. Cefdinir impurity 2 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| OBERVATION |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| OD of Mouth |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Odour |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| OFLOX-D EYE/EAR DROPS 10 ML LABELS |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ofloxacin IP 200 mg |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ofloxacin IP 50 mg: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oil Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oleic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Opening Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| optical rotation |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Organic Colors & Lakes |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Organic Compounds |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Organic Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Organic Impurities Limit of N–Methyl pyrrolidine (%w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Osmolality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| other polysaccharides |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Other related substances Total Impurities (excluding 5- Benzyl-3,6-dioxo-2-piperazineacetic acid) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer flap Height(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Dia (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Dia Bottom (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Diameter (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer diameter at base |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Diameter of Aluminium seal (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Diameter of flip off seal (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Diameter Plastic Portion (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Outer Roll Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Over flow Capacity (ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Overall Height |
8.00 mm to 8.80 mm |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oxalate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oxalic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oxidation of Roll |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oxidising Substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Oxidizable substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| p- toluene sulphonamide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| p-Hydroxybenzoic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| P. Cefdinir glyoxalic analog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| P.aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Packing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Palmitic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Palmitic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Palmitoleic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| PANTONE |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Paper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Paper Grammage |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Paper Gsm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Paper Substrate Grade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Paper with Adhesive |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Partical size : X10 |
Not more than1.0 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Partical size:X50 |
Not more than3.0 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Partical size:X90 |
Not more than5.0 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Partical size:X97 |
Not more than10.0 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle below 20# Sieve |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle below 60# Sieve |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle Size |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle size (By Malvern)-D10 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particle size (By Malvern)-D50 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particle size (By Malvern)-D90 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particle Size (by sieve) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle Size - D97 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particle Size : X95 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particle Size Distribution (Estimation by analytical sieving) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle Size-D90 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particle size: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle size: By Diffraction ( D10 ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle size: By Diffraction (D50) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle size: By Diffraction (D90) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particle size: By Diffraction (D97) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particles ≥ 10µm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particles ≥ 25µm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particles≥10pm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particles≥25pm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particulate contamination
Equal to greater than 10µm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particulate contamination
Equal to or greater than 25 µm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Particulate Matter |
NMT 6000 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Particulate Matter (per gm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pasting / pre folding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Pasting Quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pathogens |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Peel Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Penetrability |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Performance test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Peroxide value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Peroxides |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH ( 10% w/w ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH ( 2.0 g in 10 ml ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH (1.0g in 10ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH (100 mg of Cefepime per ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH (100 mg/ml ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH (125 g Sulbactam/ml and 250mg cefoperazone/ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| pH (5 % w/v aqueous solution.) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH (5.0 % w/v suspension in carbon dioxide free water ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH (Determine in solution A) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH * |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PH AFTER 7 DAYS |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pH of 2% Slurry |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pharma code No. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pharmacode value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Physical Test |
White and Black Spot should be absent. Top layer of aluminium should not leech/scratch while rubbing |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Piercing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pin hole count (Nos) * |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pin hole count (Nos)* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pin Holes |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PLAIN CARTON |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Plug Diameter |
Plug Diameter |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Plunger top Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Poly foil gsm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Poly Gsm |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Polyamide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Polymorphic Identity : By X-Ray Powder Diffraction |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Potassium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Potassium :By flame photometry and atomic absorption spectrophotometry |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Povidone (PVPK-30) IP |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Powder fineness(By sieve) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Presence of Dirt and Stain |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Preservative Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Print quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Print repeat length |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printability |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PRINTED POUCH & LAMINATED (LUPIN ) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PRINTED POUCH ST LABEL 65 X48 MM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printed text matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printing Color |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printing Matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printing Quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Printing Surface |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Propanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Protein |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Proteinous Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| pseudomonas aeruginosa |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Purity: By HPLC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PVC |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PVC BY Morpholine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PVC Flim |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PVC with Adhesive |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| PyrBulk Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pyridine Content (By HPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Pyruvic Acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Q. E-Cefdinir |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| R. Cefdinir decarboxy open ring Lactone a |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Ratio of Alkyl components. (By: HPLC.) n-C12H25 homolog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reactions of bromides-(A): |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Reactions of bromides-(B): |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Readily cabonisable substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Readily Oxidisable Substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reconstitution Time |
|
|
Seconds |
0 |
Character |
|
|
N |
N |
N |
|
| Reconstitution Time (Seconds) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Redispersibility |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reducing Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reducing Impurity |
Not more than 5.0 ml of 0.01 M ceric ammonium sulphate is required. |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reducing substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reducing sugars |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Reflect Embossing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Refractive index |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Refractive Index @20 ºC |
|
|
º |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Related Compound -A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Compound -B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substance By HPLC (%) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related substances (By UPLC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances : (By Thin Layer Chromatography) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: (By HPLC) i) Ciprofloxacin ethylene diamine analog |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: (By HPLC) ii) Any other Individual impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: (By HPLC)iii) Sum of all Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: Any secondary peak |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: By HPLC
(For Budesonide)
11-Keto Budesonide Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC
(For Budesonide)
21-dehydro budesonide Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC
(For Budesonide)
Single maximum unknown Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC
(For Budesonide)
Total Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC
(For Formoterol)
Formoterol Amine Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC
(For Formoterol)
Single Maximum Unknown Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC
(For Formoterol)
Total Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Related Substances: By HPLC (Any individual impurity) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: By HPLC (Total impurity) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: By HPLC Single maximum impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Related Substances: Sum of all secondary peaks |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Relative content of Stearic acid and Palmitic acid (GC Analysis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Relative Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Relative Index |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Release Paper |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| repeat length |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual Solvent |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual Solvent (by GC) Ethanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Residual Solvent (By GC) Isopropyl Alcohol |
Methonol |
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Residual solvent (Ethyl acetate) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent by GC (Acetone) |
Not More Than 5000 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent By GC (Methylene dichloride) |
Not More Than 600 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent by GC(Acetonitrile) |
Not More Than 410 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent by GC(Butyraldehyde) |
Not More Than 100 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual Solvent By GC(Ethyl Acetate) |
Not More Than 5000 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent By GC(Methanol) |
Not More Than 1000 |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual Solvent Methylene Chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: (By GC) 2) n-Butanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: (By GC) Methanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: (By GC) Toluene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: Acetone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: Acetonitrile |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: Butyraldehyde |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: Methanol |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: Methylene dichloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvent: By :GC Di isopropyl ether |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual Solvent: BY GC Tetrahydrofuran |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual Solvents (By GC) Diethyl ether |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Residual Solvents (By GC) Methyl ethyl ketone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Residual solvents (ppm) i)1,4 Dioxane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvents : Name of manufacturer : FEF chemicals |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residual solvents :Name of manufacturer: canton laboratories Pvt.Ltd., |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residue on evaporation |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Residue on Ignition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Resin |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Retained on 40# Mesh |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Retained on 80# Mesh |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Revision History |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Rim Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Rivision History |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Roll outer diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Rub Resistence |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| S-Methyl Fluticasone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| S. Cefdinir decarboxy open ring Lactone b |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Salmonell sp. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Salmonella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Saponification value |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Scuff Proof |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Scuff Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sealing Quality |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Second substrate (PE) GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Security measures |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Self Sealing Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Self-Sealiability |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Settling volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Shade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Shigella |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Shore a Hardness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sieve Analysis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sieve analysis (#% Fines through 60#) |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
N |
| Sieve Analysis (#40) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sieve analysis by 30 mesh |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Single Maximum Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Single Maximum unknown impurity (%): |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Size of Box |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Slot Size |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| SODIUM BISULPHITE |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| SODIUM BISULPHITE -IP |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium carbonate (%w/w) * |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium carbonate content (By Titration) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium chloride |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium chloride & sodium sulphate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium chloride and sodium Glycollate (on dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium Chloride IP |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sodium Glycollate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Solubility |
|
|
|
0 |
Character |
|
|
N |
N |
Y |
|
| Solubility ammonical solution of copper tetrammine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Soluble Chloride & Sulphate (As sodium Salt) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Solution S |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Special Instruction |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Specific Absorbance |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Specific Gravity g/ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Specific Optical Rotation |
|
|
(°) |
0 |
Character |
|
|
N |
N |
N |
|
| Specific Optical Rotation (o) (Calculate on Anhydrous basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Specific optical rotation: calculated on dried basis. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Specific rotation |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Spoon Cup Height (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Spoon Handle Width (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Spoon Total Length (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Stability of Suspension (After 4 days) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Standard Packing |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Staphylococcus aureus |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Starch |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Starch & dextrins |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Stearic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Stearic acid and Palmitic acid |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Stearic acid: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Sterile Ceftriaxone Sodium IP Eq. to Ceftriaxone |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Sterile Tazobactam Sodium Eq.to Tazobactam |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Sterility |
|
|
|
0 |
Character |
|
|
N |
Y |
N |
|
| Sterility Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sterility(Membrane filtration method) |
|
|
|
0 |
Character |
|
|
N |
Y |
N |
|
| Sterilization test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sticking |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Storage Condition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Sulbactam Related Compound A |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Related Compound B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Related Compound C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Related Compound D |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Related Compound E |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Related Compound F |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Sodium BP Eq. to au Sulbactam. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Sodium IP Eq. to Sulbactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Sodium IP Eq.to Sulbactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulbactam Sodium USP Eq.to Anhydrous Sulbactam |
|
|
% |
0 |
Numeric |
|
Range |
Y |
N |
N |
|
| Sulbactam Sodium USP Eq.to Sulbactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulfate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulfites |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulfur dioxide |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphate content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphated Ash |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphated Ash (% w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphated Ash (on dried basis) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphite |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sulphites |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sum of all secondary impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sum of impurities B and C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sum of Impurities other than A and B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Sum of impurities other than A and C |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Supply: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Surface finish |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Surface Glass Test(ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| T-1551B |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| T-1551E |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| T-1551F |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| T. Cefdinir impurity 3 |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tagger Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tagger Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| TAMC (Total aerobic microbial count) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tap density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Taped Bulk Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tapped density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tartrates |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Taste |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tazobactam on anhydrous basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tazobactam Sodium eq. to Tazobactam |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Tazobactam Sodium Eq.to Tazobactam |
|
|
% |
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Tazobactam Sodium on anhydrous basis |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Technical Defects |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| testA |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Tetradecane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Tetrahydrofuran |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Text Matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Text Matter& colour |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| The average volume of suspension should not be less than 100% of the volume declared in the labeling. (NLT 30 ml) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thiazolylglyoxalic methyloxime |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of alu. foil |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of Aluminium (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of Aluminium Wall (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of BOPP |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of metalized polyester film |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of polyester film |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness of polythene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness Of Wad(mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thickness off sheet (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Third substrate (Al foil) GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Thread Dia (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Titanium |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Toluene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Top Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Top Layer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Top Outer Diameter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Aerobic Microbial Count |
NMT 103 cfu/ml |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Aerobic Microbial Count (TAMC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Aerobic Microbial Count NMT 1000 cfu/ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total aerobic microbial count . |
Not more than 1000 cfu per g |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Ash (%) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total bacterial count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total combined molds and Yeasts count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total combined yeast and molds count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total combined Yeasts and Molds Count |
NMT 102 cfu/ml |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total combined yeasts and molds count . |
Not more than 100 cfu per g |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total combined Yeasts and Molds Count NMT 100 cfu/ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total degradation product |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total degradation product. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total degradation products(excluding Glycopyrrolate related compound C) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Total Dye Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Ethanol and Water: The sum of the percentage of Ethanol and the percentage water |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total fungi and yeast count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total fungi count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Gramage Of Aluminium Foil with VMCH/HSL/Universal HSL |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Grammage |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Grammage of
Laminate (g/m2) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Total Grammage Of Aluminum Foil |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Height |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Height (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Hight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Impurities (excluding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Impurities (excluding Compound A (Aminosulfinic acid) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total impurities other than Ethanol and 2-methylbut -2-ene |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Impurity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Organic Carbon |
NMT 8000 ppb. |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total secondary Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total unknown impurity (%) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total viable microbial count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Total Weight (mg) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Weight (gm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Yeast and Mold Count (TYMC) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Total Yeasts and Molds Count Tests for Specified Micro-Organisms: |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Transmittance |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Triethyamine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Triethylamine |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Truxone 1.0 g Sticker label |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Type |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Type Of Carton |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Type of Container |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Type of flute |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Type of Varnish |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Undecane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Uniformity of content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Uniformity of Dispersion |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Uniformity of dosage units (By weight variation) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Uniformity of dosage units By Content Uniformity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Uniformity of net filled weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Uniformity of Volume |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Uniformity of weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Uniformity of weight
Fill weight (Average) (20 vial) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Unsaponifiable Matter (%w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Unspecified Impurities |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Unsulfonated primary aromatic amine (Calculated as Aniline) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Untaped Bulk Density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Unwinding direction |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| User Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| v)Dichloro methane |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Validation |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Varnish |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Varnish Details |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Varnish Grade |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| vi)Ethyl Acetate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| vii)Methyl isobutyl ketone |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| viii)N-Butyl acetate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Vinylpyrrolidinone. |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Viscosity |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Viscosity by Rotational Methods mPa.s |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Visible |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Visual defects* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Visual Foreign Matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Visual Inspection |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Visual Inspection* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Visual Test |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| VMCH Coating |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| VMCH GSM |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Volatile matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Volatile Oil Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Volatile Sulphides |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Volume check |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Volume in Container |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| wad density |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Wall Thickness |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water |
Not more than 3.00% w/w |
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (% W/W) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (% w/w) (Use 0.5 g of sample) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (% W/W) (Use 1.0 g of Sample) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (%w/w) (Use 0.4 g of sample). |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (%w/w). (Use 0.3g of sample)* |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (%w/w).(Use 0.15gm of sample) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water (KF) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Water (Method I) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water by KF ( % w/w) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water by KF ( % w/w) (Use 0.2g sample). |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water by KF (%w/w) (Use 0.1g sample) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water Content |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water Content (%w/w) (Determined on 0.5 g) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water determination |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water insoluble matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water soluble substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water-insoluble matter |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water-soluble substances |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Water: By Karl Fischer |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight (g) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight of without wad (g) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight Of 10Flip Off Seal (gm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight Of Wad (GM) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight per ml |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Weight per ml@20ºC |
|
|
|
0 |
Numeric |
|
Range |
N |
N |
N |
|
| Weight-Of Tagger (Wad) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Width |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Width (mm) |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Width After Folding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
N |
| Width of folding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Width of Partition |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Winding |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Winding direction |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| winding of Roll |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Yeast & Mold/G |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Yeast and Mould Count |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| Zinc stearate |
|
|
|
0 |
Character |
|
|
N |
N |
N |
|
| ZPL Validation Test |
Validation Test |
|
|
0 |
Character |
|
|
N |
N |
N |
|